Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.66 |
| ▸ | HRH2 | P25021 | 4/20 | 0.66 |
| ▸ | HRH1 | P35367 | 4/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544791 | 0.92 | LTA4H (0.80) | LTA4HHRH3HRH2HRH1TMEM97 | |
| SCHEMBL6278104 | 0.92 | LTA4H (0.80) | LTA4HHRH3HRH2HRH1TMEM97 | |
| SCHEMBL6398998 | 0.92 | LTA4H (0.80) | LTA4HHRH3HRH2HRH1TMEM97 | |
| SCHEMBL30272050 | 0.84 | KDM4E (0.60) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL30395141 | 0.84 | KDM4E (0.60) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL27512013 | 0.84 | HRH3 (0.58) | LTA4HHRH3HRH2HRH1TMEM97 | |
| SCHEMBL19897903 | 0.84 | KDM4E (0.60) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL19897905 | 0.84 | KDM4E (0.60) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL21621022 | 0.84 | KDM4E (0.64) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL19389940 | 0.84 | LTA4H (0.67) | LTA4HHRH3HRH2HRH1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | claimed |
| US-7192978-B2 | Pyrrolidinium derivatives | ALMIRALL PRODESFARMA AG (CH) | 2007-03-20 | — | — | US | claimed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | claimed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | claimed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | claimed |
| US-20070129420-A1 | New pyrrolidinium derivatives | ALMIRALL PRODESFARMA SA | 2007-06-07 | — | — | US | disclosed |
| US-7192978-B2 | Pyrrolidinium derivatives | ALMIRALL PRODESFARMA AG (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | disclosed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282875-A1 | Pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | LTA4H 1194/4885HRH3 189/4885HRH2 114/4885 |
| US-20070129420-A1 | New pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | LTA4H 1227/4885HRH3 204/4885HRH2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.